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Summary Features of 111 mammary carcinomas derived from breast cancer screening were compared with
those of 69 carcinomas presenting 'clinically'. Screen detected cancers were smaller, had less likelihood of
nodal metastases, included a higher proportion of in situ tumours and if invasive, tended to be of lower grade.
Using immunohistochemical methods, the expression of c-erbB-2 oncoprotein, epidermal growth factor
receptor (EGFR) and cathepsin D were compared in the two groups. A similar proportion of screened and
unscreened tumours expressed c-erbB-2 oncoprotein and EGFR but expression of the oestrogen regulated
protein cathepsin D was significantly more frequent in the screened group (P<0.05). Although a relatively
small series, the results suggest a biological difference between 'screened' and 'clinical' tumours.
Whether or not breast cancer screening results in a reduction
in mortality from the disease, it is clear from several studies
that screening yields tumours that are smaller, more likely to
be in situ and clinically less advanced (Linell et al., 1980;
Gibbs, 1985; Anderson et al., 1986; Roberts et al., 1990). The
question arises as to whether screen detected cancers differ
biologically from those presenting clinically; the aim of this
study was to determine whether the two groups differed in
their expression of antigens that are associated with differing
biological behaviour in terms of prognosis. Three antigens,
currently of interest as prognostic indicators were chosen.
Amplification of c-erbB-2 is regarded as a reliable prognostic
marker in breast cancer (Barnes, 1989), epidermial growth
factor receptor (EGFR) correlates strongly with a short
disease free interval (Lewis et al., 1990) and positive immuno-
staining for the oestrogen regulated protein cathepsin D is
associated with prognostic advantage (Henry et al., 1990).
Materials and methods
Tumour tissue from 180 carcinomas was studied. Of these, 69
tumours derived from clinical presentation whereas 111
tumours were detected by breast cancer screening. The latter
group comprised 80 tumours detected by population screen-
ing (UK National Health Service Breast-Screening Pro-
gramme) and 31 tumours via a charity-sponsored breast
screening service. The symptomatic tumours were from con-
secutive patients investigated and treated at the same hospital
over the same period of time as those of the screened group.
Specimens were obtained immediately after removal,
measured and described, and when possible a portion of
tumour snap frozen and stored at - 70°C. Representative
blocks were fixed immediately in 10% buffered formol saline
and one block post fixed in mercuric chloride.
All invasive tumours (ductal and lobular) were graded by
Elston's modification of the Bloom and Richardson method
(Elston, 1987). The immunohistochemical preparations were
independently scored by two observers without knowledge of
the derivation of the tumours; discrepancies were resolved by
conference with a two headed microscope.
Immunohistochemistry
c-erbB-2 oncoprotein Paraffin sections of tissue postfixed in
mercuric chloride were cut at 4 1f, dewaxed and rehydrated.
After treatment with 0.5% hydrogen peroxide in methanol
for 10 min the sections were washed and placed in TRIS-
buffered saline (TBS) for 5 min. They were then covered with
1/5 normal swine serum for 10 min after which excess serum
was removed and replaced by mouse monoclonal antibody
(NCL-CBl [Corbett et al., 1990]) diluted 1:20. The sections
were incubated in a humid chamber at 4°C overnight. After
two changes of TBS they were incubated for 30 min with
biotinylated sheep-anti-mouse serum (Amersham) and strept-
avidin-biotin peroxidase complex for 30 min, being washed
with TBS between stages. Diaminobenzidene was used as a
chromagen with copper sulphate as enhancement and the
sections were counterstained with Carazzi's haematoxylin.
Tumours were scored by assessment of intensity of mem-
brane associated staining and the proportion of tumour cells
stained, as previously described (Wright et al., 1989), and
thus placed in three categories: 2, strong staining in at least
50% of tumours cells; 1, any positive staining less than 2; 0,
no staining.
EGFR Frozen sections (51) were cut at 4°C and dried
overnight at room temperature (RT). After fixation in ace-
tone for 10 min at RT the tissue was incubated with 1/5
normal swine serum for 10 min before incubation for 30 min,
with monoclonal anti-EGFR (EGF-RI [Waterfield et al.,
1982], Amersham) diluted 1/40 in 1/5 normal swine serum.
The sections were then incubated for 30min with biotiny-
lated sheep-anti-mouse serum (Amersham) and streptavidin-
biotin peroxidase complex for 30min, being washed with
TBS between stages. The chromagen and counterstain were
as for the c-erbB-2 method above. A section of human
placenta was used as a control.
Tumours were scored on a basis of intensity and distribu-
tion of staining as previously described (Horne, 1987). Both
membrane and cytoplasmic staining was considered. Car-
cinomas showing definite labelling of greater than 25% of
tumour cells were regarded as 'positive'.
Cathepsin D Paraffin sections were cut at 4 ts, dewaxed,
rehydrated and treated with hydrogen peroxide in methanol
as for c-erbB-2 above. They were next treated with 0.1%
trypsin at 37°C for 10 min and washed in water. After rinsing
in TBS and incubation with normal 1/5 swine serum for
10 min as above, they were incubated with the primary anti-
serum (anti-cathepsin D [Reid et al., 1986]) diluted 1:400 for
30 min at RT. After two changes of TBS they were incubated
with biotinylated donkey-anti-rabbit serum (Amersham) and
streptavidin-biotin peroxidase complex for 30 min, being
washed with TBS between stages. The chromagen and
counterstain were as for the c-erbB-2 method above.
Tumours were scored for intensity of staining as previously
described (Henry et al., 1990) and placed in three grades, 0,
no cell staining; 1, moderate staining; 2, strong staining.
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Staining of macrophages was ignored. For this study tumour
staining ofgrade 1 or 2 was regarded as positive for purposes
of analysis.
Results
Size, grade, invasion status, lymph node status
Our results demonstrate certain differences between screen
detected cancers and those presenting clinically. Tumours
within the screened group were more often of small size; 37%
of screened tumours measured less than 15 mm compared
with 15% ofclinical tumours (P<0.005, Figure 2c). Further,
whereas tumour grades were fairly evenly distributed in the
clinical group, the screened group contained relatively few
grade III lesions (P<0.025, Figure 2d). Differences were also
evident in the invasion status, in situ disease being un-
common (3%) in the clinical cases yet comprising 16% of
screened tumours (P<0.05, Figure 2b). This difference is
reflected in the lymph node status where 35% of the clinical
cases had axillary metastases compared with 14% of screened
patients (Figure 2a).
Immunohistochemistry
Immunostaining for EGFR using monoclonal antibody
EGFR1 showed generally a cytoplasmic pattern, although in
some cases membrane associated labelling was observed
(Figure la). Immunostaining for c-erbB-2 using monoclonal
antibody NCL-CB 11 gave, in all positive cases, intense mem-
brane associated staining (Figure lb). Using the polyclonal
antiserum, for cathepsin D a granular cytoplasmic staining
pattern was observed (Figure lc).
Comparing screened and unscreened tumours, there was a
significant difference in the expression of cathepsin D
between the two groups. Almost equal positive and negative
scores were recorded in the clinical group, whereas there was
a marked tendency towards cathepsin D positivity in the
screened group (P<0.05, Figure 3a). Eliminating non-inva-
sive carcinomas from the analysis and considering invasive
carcinomas only, an excess of cathepsin D positive tumours
was observed in the screened group, although falling just
short of significance (Figure 3b). A similar proportion of
patients in the screened and unscreened groups expressed
EGFR and c-erbB-2 (Figure 4a and b).
Invasion status did not relate to cathepsin D expression or
EGFR expression. Whilst a higher proportion of in situ
tumours were c-erbB-2 positive (5/19:' 26%) compared to
invasive lesions (20/139: 14%), this did not achieve signi-
ficance. There was a significant tendency towards co-express-
ion of c-erbB-2 and EGFR (P<0.01, Figure 5a). There was
a significant association between high histological grade and
positive c-erbB-2 status (Figure Sb).
Discussion
The patients within our screen detected group were largely
from a prevalence screen, i.e. the first screen a patient has,
detecting all prevalent disease. As expected, this yielded a
number of large tumours, often palpable, measuring up to
60 mm and other examples of advanced disease. All but four
the tumours were clinically stage I or II. None had evident
distant metastases but skin was locally involved in two
patients from each group. Despite this bias, diluting the
screened group with tumours that would not be expected
within second and subsequent (incidence) screens, our results
demonstrate certain differences between the screen detected
cancers and those presenting clinically. The differences relat-
ing to smaller size, lower grade, higher incidence of in situ
disease and lower incidence of lymph node metastases within
the screened group are in accordance with previous work
(Gibbs, 1985; Anderson et al., 1986).
Overexpression of c-erbB-2 oncoprotein is regarded by
Figure 1 a, Invasive ductal carcinoma of breast: immunohisto-
chemical staining for EGFR using monoclonal antibody EGFR1.
Note both cytoplasmic and membrane associated labelling. b,
Invasive ductal carcinoma of breast: immunohistochemical stain-
ing for c-erbB-2 oncoprotein using monoclonal antibody NCL-
CBI 1. Note intense membrane associated staining of tumour cells
and absence ofstaining ofnon-neoplastic epithelium (centre, left).
c, Invasive ductal carcinoma of breast: immunohistochemical
staining for cathepsin D using rabbit polyclonal antiserum. Note
the fine granular cytoplasmic staining for this lysosomal enzyme.
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Figure 3 Presentation mode related to cathepsin D expression.
Note the excess of cathepsin D positive tumours in the screened
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Figure 2 Presentation mode related to lymph node status a,
invasion status b, tumour size c and tumour histological grade d.
Screened cancers tend to be lymph node negative, non-invasive,
small and of low histological grade, compared to the non-
screened group.
most workers to equate with poor prognosis (Barnes, 1989;
Slamon et al., 1987; Wright et al., 1989; Varley et al., 1987;
Zhou et al., 1987) although this is not a universal finding,
perhaps due to differences in methodology between authors
(Press, 1990). In our experience, staining for c-erbB-2 protein
is enhanced by post fixation of the formalin-fixed tissue by
mercuric chloride; without standardisation of methods, rates
of expression cannot be compared between different groups
of workers. There is general agreement, however, that over-
expression is frequently found in DCIS of the comedo, large
cell type (van de Vijver et al., 1988). It might have been
expected that overexpression of c-erbB-2 protein, associated
as it is with poorer prognosis, would be more frequent in our
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Figure 4 Presentation mode related to c-erbB-2 expression. The
proportion of c-erbB-2 positive cases in each group is similar: a,
all cases, b, invasive carcinomas only.
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Figure 5 a, Tumour c-erbB-2 status related to EGFR status.
There is significant co-expression of the two proteins. b, Tumour
c-erbB-2 staining related to histological grade. There is a signi-
ficant association between c-erbB-2 expression and higher histo-
logical grade.
'clinical' group of tumours; our finding of equal incidence of
expression in the two groups is perhaps due to the higher
proportion of DCIS within the screened group. The number
of cases falling into the c-erbB-2 positive category is, how-
ever, small in the series of tumours collected so far, and it
may be that differences between screened and unscreened
cases will emerge with greater numbers.
Again, the presence of epidermal growth factor receptor in
human breast cancer is associated with poor prognosis
(Sainsbury et al., 1985; Sainsbury et al., 1987) although not
with tumour size or lymph node status (Sainsbury et al.,
1987; Sainsbury et al., 1988; Toi et al., 1990); some workers
find an association with histological grade (Toi et al., 1990)
whereas others do not (Lewis et al., 1990). The proportion of
cases overall scored positive for EGFR was 30% (40/132)
and was similar to that assessed as 'positive' by Sainsbury et
al. (1987) using radioligand binding assays, but somewhat
higher than the proportion scored positive by Lewis et al.
(1990) (14%) who also used an immunohistochemical
method. The differences in tumour size, lymph node status
and grade that we find between the screened and 'clinical'
groups are not reflected in the EGFR status that is essentially
similar in the two groups, but our results do demonstrate an
association between expression of EGFR and c-erbB-2 pro-
tein. There have been no previous reports of co-expression of
c-erbB-2 and EGFR and this may be a chance finding.
Patients shown to express both proteins have a particularly
poor prognosis (Wright, 1989).
Cathepsin D is an aspartic proteinase, a proteolytic
enzyme widely distributed in human tissues and often ex-
pressed in mononuclear phagocytes (Reid et al., 1986). It is
synthesised in the form of a precursor and in the human
breast is secreted in greater amount by cancer cells than by
normal mammary cells (Capony et al., 1989). Westley and
Rochefort reported in 1979 that a glycoprotein subsequently
identified as cathepsin D and secreted into culture medium
by human breast cancer cells was oestrogen regulated (West-
ley & Rochefort, 1979). The prognostic significance of raised
levels of cathepsin D within breast cancer tissues is disputed.
Several groups of workers have associated high levels of
cathepsin D expression within primary breast cancer with
poor prognosis (Maudelonde et al., 1988; Thorpe et al., 1989;
Spyratos et al., 1989; Tandon et al., 1990) yet Henry et al.
(1990) found in lymph node positive patients that overex-
pression of cathepsin D was associated with considerable
prognostic advantage. One possible explanation for this dis-
crepancy is that the studies equated high levels of cathepsin
D with poor prognosis have examined extracts of breast
cancer tissue whereas Henry et al. (1990) employed a poly-
clonal antibody in an immunohistochemical study. Cathepsin
D is found in high concentration within macrophages and
extracts of high grade, perhaps necrotic tumours rich in
inflammatory cells would be likely to contain high levels of
the protein irrespective of its concentration within the
tumour epithelial cells.
The method used in the present study, almost identical to
that of Henry et al. (1990), employed the same antibody, and
the overall positivity rate, using the same method of scoring,
was very similar. The results demonstrate a difference
between the screened and clinical groups of patients with
respect to cathepsin D expression; in the clinical group
almost equal numbers were scored as either positive or
negative whereas in the screened group positive scoring was
more than twice as frequent as negative (Figure 3a and 3b).
In seeking an explanation for this finding it hardly seems
likely that the screened group of patients contain a higher
proportion carrying a poorer prognosis; whatever the value,
if any, of breast cancer screening there is nothing in the
literature to suggest that it is selective in this manner. Henry
et al. (1990) found a significant association between positive
oestrogen receptor status and immunohistochemically detect-
ed cathepsin D and postulated that cathepsin D positivity
provides additional information on the functional integrity of
the oestrogen response pathway; cathepsin D expression in
oestrogen receptor-negative patients was not associated with
prognostic advantage. There is evidence to suggest that every
breast cancer contains steroid receptors from its inception
but that as the disease advances the numbers of oestrogen -
and progesterone - receptor positive tumours decreases
(Clark et al., 1984; Stebbings et al., 1989; Tinnemans et al.,
1990). Our results, although based on a relatively small
series, therefore lend further credence to the view that screen
detected breast cancers do indeed represent tumours at an
earlier stage in their development. An alternative interpreta-
tion of this finding is suggested by the fact that the apparent
incidence of invasive breast cancer in screened populations is
at least 40% higher than in an equivalent non-screened group
(UK Trial, 1988). This indicates that many of the cancers
detected by screening would not have presented clinically, for
whatever reason (slow growth, regression). Thus the increas-
ed expression of cathepsin D may reflect the possibility that
screening picks up, in part, cancers that are biologically
distinct from those presenting clinically. The fact that cathep-
sin D is a marker of less aggressive tumour behaviour
supports the view that screened cancers tend to be better
differentiated and might never have presented clinically, or
have pursued a relatively benign course without metastasis.
This hypothesis would explain in part failure of some screen-
ing programmes to yield a significant reduction in mortality
(UK Trial, 1988).
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